Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Nutrients 2013, 5(7), 2475-2482; doi:10.3390/nu5072475
Article

Metformin Lowers Serum Cobalamin without Changing Other Markers of Cobalamin Status: A Study on Women with Polycystic Ovary Syndrome

1,* , 2
, 1
, 3
 and 1
Received: 26 April 2013; in revised form: 5 June 2013 / Accepted: 7 June 2013 / Published: 5 July 2013
(This article belongs to the Special Issue Vitamin B12 and Human Health)
View Full-Text   |   Download PDF [449 KB, uploaded 5 July 2013]
Abstract: Treatment with the anti-diabetic drug metformin is followed by a decline in plasma cobalamin, but it is unsettled whether this denotes an impaired cobalamin status. This study has explored changes in the markers of cobalamin status in women with Polycystic Ovary Syndrome treated with metformin (1.5–2.5 g per day) (n = 29) or placebo (n = 23) for six months. Serum samples were collected before and after two, four, and six months of treatment. We found serum cobalamin to decline and reach significant lower levels after six months of treatment (p = 0.003). Despite the decline in serum cobalamin, we observed no reductions in the physiological active part of cobalamin bound to transcobalamin (holotranscobalamin), or increase in the metabolic marker of cobalamin status, methylmalonic acid. Instead, the non-functional part of circulating cobalamin bound to haptocorrin declined (p = 0.0009). Our results have two implications: The data questions whether metformin treatment induces an impaired cobalamin status in PCOS patients, and further suggests that serum cobalamin is a futile marker for judging cobalamin status in metformin-treated patients.
Keywords: vitamin B12; cobalamin; metformin; Polycystic Ovary Syndrome; haptocorrin; holotranscobalamin vitamin B12; cobalamin; metformin; Polycystic Ovary Syndrome; haptocorrin; holotranscobalamin
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Greibe, E.; Trolle, B.; Bor, M.V.; Lauszus, F.F.; Nexo, E. Metformin Lowers Serum Cobalamin without Changing Other Markers of Cobalamin Status: A Study on Women with Polycystic Ovary Syndrome. Nutrients 2013, 5, 2475-2482.

AMA Style

Greibe E, Trolle B, Bor MV, Lauszus FF, Nexo E. Metformin Lowers Serum Cobalamin without Changing Other Markers of Cobalamin Status: A Study on Women with Polycystic Ovary Syndrome. Nutrients. 2013; 5(7):2475-2482.

Chicago/Turabian Style

Greibe, Eva; Trolle, Birgitta; Bor, Mustafa V.; Lauszus, Finn F.; Nexo, Ebba. 2013. "Metformin Lowers Serum Cobalamin without Changing Other Markers of Cobalamin Status: A Study on Women with Polycystic Ovary Syndrome." Nutrients 5, no. 7: 2475-2482.



Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert